Therapy Name | RNA CART19 cells |
Therapy Description |
Limited information is currently available on RNA CART19 cells, putative autologous T cells electroporated with RNA expressing CD19 chimeric antigen receptors consists of TCR zeta and 4-1BB costimulatory domains (Aug 2018). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RNA CART19 cells | Limited information is currently available on RNA CART19 cells, putative autologous T cells electroporated with RNA expressing CD19 chimeric antigen receptors consists of TCR zeta and 4-1BB costimulatory domains (Aug 2018). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02624258 | Phase I | RNA CART19 cells | Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | Recruiting |